Graig Suvannavejh
Stock Analyst at Mizuho
(4.55)
# 262
Out of 5,134 analysts
171
Total ratings
57.36%
Success rate
20.86%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMX Immix Biopharma | Initiates: Outperform | $14 | $8.12 | +72.41% | 1 | Feb 9, 2026 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $205 | $79.92 | +156.51% | 1 | Jan 7, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $12.45 | -59.84% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $39.58 | +36.43% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $175.84 | +10.33% | 2 | Dec 2, 2025 | |
| INSM Insmed | Maintains: Outperform | $196 → $256 | $150.52 | +70.08% | 12 | Dec 1, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $36.92 | +24.59% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $62.78 | +59.29% | 1 | Nov 20, 2025 | |
| IMTX Immatics | Maintains: Outperform | $19 → $23 | $9.93 | +131.62% | 4 | Nov 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $54 → $56 | $80.48 | -30.42% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $46 | $30.76 | +49.54% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $183.30 | +10.20% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $19 | $21.57 | -11.91% | 11 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.58 | +153.16% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.40 | +7,437.69% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $1.97 | +77.66% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.54 | +41.24% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $5.12 | +95.31% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $17.49 | -37.11% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $14.91 | +74.38% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $14.13 | -43.38% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $32.43 | +1.76% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.51 | +403.31% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $7.52 | +884.04% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.84 | -64.79% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $102.53 | -65.86% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $22.66 | -64.70% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $66.62 | -14.44% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $29.06 | -82.79% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $10.77 | +215.69% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $10.12 | +176.68% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $30.06 | +3.13% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $12.98 | +2,827.58% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.71 | +178.59% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $26.61 | +35.29% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $33.93 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $2.11 | +1,653.55% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $167.98 | -23.80% | 1 | Sep 14, 2020 |
Immix Biopharma
Feb 9, 2026
Initiates: Outperform
Price Target: $14
Current: $8.12
Upside: +72.41%
Palvella Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $205
Current: $79.92
Upside: +156.51%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $12.45
Upside: -59.84%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $39.58
Upside: +36.43%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $175.84
Upside: +10.33%
Insmed
Dec 1, 2025
Maintains: Outperform
Price Target: $196 → $256
Current: $150.52
Upside: +70.08%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $36.92
Upside: +24.59%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $62.78
Upside: +59.29%
Immatics
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $9.93
Upside: +131.62%
Halozyme Therapeutics
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $80.48
Upside: -30.42%
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $30.76
Upside: +49.54%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $183.30
Upside: +10.20%
Nov 3, 2025
Maintains: Neutral
Price Target: $24 → $19
Current: $21.57
Upside: -11.91%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.58
Upside: +153.16%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.40
Upside: +7,437.69%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $1.97
Upside: +77.66%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.54
Upside: +41.24%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $5.12
Upside: +95.31%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $17.49
Upside: -37.11%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $14.91
Upside: +74.38%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $14.13
Upside: -43.38%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $32.43
Upside: +1.76%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.51
Upside: +403.31%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $7.52
Upside: +884.04%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.84
Upside: -64.79%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $102.53
Upside: -65.86%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $22.66
Upside: -64.70%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $66.62
Upside: -14.44%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $29.06
Upside: -82.79%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $10.77
Upside: +215.69%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $10.12
Upside: +176.68%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $30.06
Upside: +3.13%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $12.98
Upside: +2,827.58%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.71
Upside: +178.59%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $26.61
Upside: +35.29%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $33.93
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $2.11
Upside: +1,653.55%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $167.98
Upside: -23.80%